Seroprevalence of the SARS-CoV-2 antibody in healthcare workers: a multicentre cross-sectional study in 10 Colombian cities

Malagón-Rojas, Jeadran; Mercado-Reyes, Marcela; Toloza-Pérez, Yezith G; Parra-Barrera, Eliana L.; Palma, Marién; Muñoz, E F Jaime; López, Ronald; Almentero, Julia; Rubio, Vivian; Ibáñez, Edgar; Téllez, Eliana; Delgado, Gabriela; Jimenez, Claudia P; Viasus, Diego; Galindo, Marisol; Lagos, Luisa

doi:10.1136/oemed-2021-107487

Cited by 12 publications

(10 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The seroprevalence reported globally range between 3% and 51%, increasing with the progression of the pandemic [ 1 , 5 – 7 ]. In our study, the seroprevalence was lower than that reported for Bogotá’s population (29.9%) [ 20 ] and that previously reported for HCWs in Bogotá (34%) [ 14 ] in studies with similar time frames as our study. This may indicate that in healthcare institutions with proper availability of PPE and adherence to its use, as in ours (97.4%), HCWs may have an infection risk similar to or lower than that in the community.…”

Section: Discussioncontrasting

confidence: 71%

“…Even though several studies have assessed the burden of SARS-CoV-2 infection in HCWs, data from low- and middle-income countries such as Colombia are scarce, especially concerning the incidence of SARS-CoV-2 and associated factors. In a previous study conducted in 10 major cities in Colombia, the seroprevalence of SARS-CoV-2 in the HCWs was 35% from September to November 2020 [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cumulative incidence, prevalence, seroconversion, and associated factors for SARS-CoV-2 infection among healthcare workers of a University Hospital in Bogotá, Colombia

et al. 2022

View full text Add to dashboard Cite

This study aimed to determine the cumulative incidence, prevalence, and seroconversion of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its associated factors among healthcare workers (HCWs) of a University Hospital in Bogotá, Colombia. An ambispective cohort was established from March 2020 to February 2021. From November 2020 to February 2021, SARS-CoV-2 antibodies were measured on two occasions 14–90 days apart to determine seroprevalence and seroconversion. We used multivariate log-binomial regression to evaluate factors associated with SARS-CoV-2 infection. Among 2,597 HCWs, the cumulative incidence of infection was 35.7%, and seroprevalence was 21.5%. A reduced risk of infection was observed among those aged 35–44 and ≥45 years (adjusted relative risks [aRRs], 0.84 and 0.83, respectively), physicians (aRR, 0.77), those wearing N95 respirators (aRR, 0.82) and working remotely (aRR, 0.74). Being overweight (aRR, 1.18) or obese (aRR, 1.24); being a nurse or nurse assistant (aRR, 1.20); working in the emergency room (aRR, 1.45), general wards (aRR, 1.45), intensive care unit (aRR, 1.34), or COVID-19 areas (aRR, 1.17); and close contact with COVID-19 cases (aRR, 1.47) increased the risk of infection. The incidence of SARS-CoV-2 infection found in this study reflects the dynamics of the first year of the pandemic in Bogotá. A high burden of infection calls for strengthening prevention and screening measures for HCWs, focusing especially on those at high risk.

show abstract

Section: Discussioncontrasting

confidence: 71%

Section: Introductionmentioning

confidence: 99%

Cumulative incidence, prevalence, seroconversion, and associated factors for SARS-CoV-2 infection among healthcare workers of a University Hospital in Bogotá, Colombia

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The seroprevalence in the general population estimated in the SAPRIS study 12 in the same geographical area (Greater Paris) in May 2020, corresponding to M1 in the SEROCOV study, was significantly lower than in the SEROCOV first-line HCWs: 6.4% in the 20- to 59-year-old population of the SAPRIS study (using a similar anti-nucleoprotein assay and considering weak positive as positive as in SEROCOV) versus 13.3% in SEROCOV ( p < 0.0001). Previous published HCW surveys reported seroprevalence ranging from 3.4 to 38% 13 , 14 . However, the heterogeneity in type of HCW tested, type of assay used, period of testing and countries with incomparable SARS-CoV-2 epidemic burden precludes a face-to-face comparison.…”

Section: Discussionmentioning

confidence: 97%

Cumulative incidence of SARS-CoV-2 infection and associated risk factors among frontline health care workers in Paris: the SEROCOV cohort study

Hausfater

Boutolleau

Lacombe

et al. 2022

Sci Rep

View full text Add to dashboard Cite

With the COVID-19 pandemic, documenting whether health care workers (HCWs) are at increased risk of SARS-CoV-2 contamination and identifying risk factors is of major concern. In this multicenter prospective cohort study, HCWs from frontline departments were included in March and April 2020 and followed for 3 months. SARS-CoV-2 serology was performed at month 0 (M0), M1, and M3 and RT-PCR in case of symptoms. The primary outcome was laboratory-confirmed SARS-CoV-2 infection at M3. Risk factors of laboratory-confirmed SARS-CoV-2 infection at M3 were identified by multivariate logistic regression. Among 1062 HCWs (median [interquartile range] age, 33 [28–42] years; 758 [71.4%] women; 321 [30.2%] physicians), the cumulative incidence of SARS-CoV-2 infection at M3 was 14.6% (95% confidence interval [CI] [12.5; 16.9]). Risk factors were the working department specialty, with increased risk for intensive care units (odds ratio 1.80, 95% CI [0.38; 8.58]), emergency departments (3.91 [0.83; 18.43]) and infectious diseases departments (4.22 [0.92; 18.28]); current smoking was associated with reduced risk (0.36 [0.21; 0.63]). Age, sex, professional category, number of years of experience in the job or department, and public transportation use were not significantly associated with laboratory-confirmed SARS-CoV-2 infection at M3. The rate of SARS-CoV-2 infection in frontline HCWs was 14.6% at the end of the first COVID-19 wave in Paris and occurred mainly early. The study argues for an origin of professional in addition to private life contamination and therefore including HCWs in the first-line vaccination target population. It also highlights that smokers were at lower risk.Trial registration The study has been registered on ClinicalTrials.gov: NCT04304690 first registered on 11/03/2020.

show abstract

“…The crude proportion shows the proportion of the participants who were reactive. To determine the real proportion of seroreactivity, an adjustment was performed based on the sensitivity and specificity of the ADVIA Centaur COV2, as previously reported [ 23 ]. The figure also presents the prevalence of total antibodies against COVID-19 during the study (days 0, 30, 60, 90, and 210).…”

Section: Resultsmentioning

confidence: 99%

“…The overall crude frequencies of seropositivity tests were estimated. Then crude seroprevalence was adjusted by using the Bayesian method in R V.2.21.2 (package RStan), using the sensitivity and specificity data reported in previous studies carried out by using a chemiluminescence immunoassay (CLIA) in Colombian populations [ 23 ]. The 95% Bayesian confidence intervals were obtained.…”

Section: Methodsmentioning

confidence: 99%

Comparison of Anti-SARS-CoV-2 IgG Antibody Responses Generated by the Administration of Ad26.COV2.S, AZD1222, BNT162b2, or CoronaVac: Longitudinal Prospective Cohort Study in the Colombian Population, 2021/2022

et al. 2022

View full text Add to dashboard Cite

To mitigate the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), vaccines have been rapidly developed and introduced in many countries. In Colombia, the population was vaccinated with four vaccines. Therefore, this research aimed to determine the ability of the vaccines introduced in the National Vaccination Plan to prevent SARS-CoV-2 infection and induce seroconversion and sought to investigate the longevity of antibodies in the blood. We conducted a prospective, nonprobabilistic, consecutive cross-sectional cohort study in a population with access to vaccination with CoronaVac, Ad26.COV2.S, AZD1222, and BNT162b2 from March 2021 to March 2022. The study included 1327 vaccinated people. A plurality of participants were vaccinated with BNT162b2 (36.1%; n = 480), followed by Ad26.COV2.S (26.9%; n = 358), CoronaVac (24%; n = 331), and AZD1222 (11.9%; n = 158). The crude seroprevalence on day zero varied between 18.1% and 57.8%. Participants who received BNT162b2 had a lower risk of SARS-CoV-2 infection than those who received the other vaccines. Participants who were immunized with BNT162b2 and AZD1222 had a higher probability of losing reactivity on day 210 after receiving the vaccine.

show abstract

Seroprevalence of the SARS-CoV-2 antibody in healthcare workers: a multicentre cross-sectional study in 10 Colombian cities

Cited by 12 publications

References 43 publications

Cumulative incidence, prevalence, seroconversion, and associated factors for SARS-CoV-2 infection among healthcare workers of a University Hospital in Bogotá, Colombia

Cumulative incidence, prevalence, seroconversion, and associated factors for SARS-CoV-2 infection among healthcare workers of a University Hospital in Bogotá, Colombia

Cumulative incidence of SARS-CoV-2 infection and associated risk factors among frontline health care workers in Paris: the SEROCOV cohort study

Comparison of Anti-SARS-CoV-2 IgG Antibody Responses Generated by the Administration of Ad26.COV2.S, AZD1222, BNT162b2, or CoronaVac: Longitudinal Prospective Cohort Study in the Colombian Population, 2021/2022

Contact Info

Product

Resources

About